瑞康医药集团股份有限公司 关于2024年前三季度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 10 月 30 日召开第五届董事会第九次会议、第五届监事会第九次会议，分别审议通 过了《关于 2024 年前三季度利润分配的议案》，本议案尚需提交公司股东大会 审议。现将具体情况公告如下： 一、2024 年三季度利润分配方案内容 根据公司 2024 年前三季度财务报表（未经审计），公司 2024 年 1-9 月份合 并报表归属于上市公司股东的净利润为 38,806,313.59 元。截至 2024 年 9 月 30 日，公司合并报表中期末未分配利润为 313,543,568.52 元。2024 年前三季度利润 分配预案为：以总股本 1,504,710,471 股为基数，向全体股东按每 10 股派发现 金红利 0.07 元（含税），按照截至本公告日总股本数量测算，预计派发现金股 利 10,532,973.30 元，不以公积金转增股本，不送红股。 本次利润分配共计派发金额未超 ...

证券时报e公司讯，第三届山东人才创新发展大会暨第十三届"海洽会"10月28日在山东大厦举办。 会上，瑞康医药与中国工程院院士、哈尔滨医科大学原校长杨宝峰院士签订中医智能辅助诊疗与配药系 统产业化项目合作协议，这是烟台市唯一一个生物医药领域的签约项目，也是首批省级数字产业重点项 目。 后期瑞康医药将与杨院士在此项目上开展全方位合作。 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2024-029 瑞康医药集团股份有限公司 关于全资子公司为上市公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、担保情况概述 瑞康医药集团股份有限公司（以下简称"公司"）于 2022 年 10 月 28 日召 开第四届董事会第二十三次会议，审议通过了《关于公司及全资、控股子公司向 境内外相关金融机构申请综合授信额度调整的议案》，同意公司及全资、控股子 公司向境内外相关银行申请总额不超过 100 亿元人民币的综合授信额度。具体 内容详见公司于 2022 年 10 月 31 日在《中国证券报》、《证券时报》、《证券 日报》、《上海证券报》及巨潮资讯网（http://www.cninfo.com.cn）披露的《第 四届董事会第二十三次会议决议的公告》（公告编号：2022-050）。 根据公司经营发展需要，公司向下述列表中的金融机构及银行申请合计不超 过人民币 6.65 亿元综合授信额度。公司全资子公司瑞康医药（山东）有限公司 （以下简称"瑞康山东"）、湖南瑞康康达健康产业开发有限公司（以下 ...

关于"质量回报双提升"行动方案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 证券代码：002589 证券简称：瑞康医药 公告编号：2024-028 瑞康医药集团股份有限公司 瑞康医药集团股份有限公司(以下简称"公司")认真践行中央政治局会议提 出的"要活跃资本市场、提振投资者信心"及国务院常务会议提出的"要大力提 升上市公司质量和投资价值"的指导思想，公司结合自身发展战略、经营情况及 财务情况，制定"质量回报双提升"行动方案。具体举措如下： 一、药械物流配送主业走出低谷，巩固公司发展基础 公司拥有众多国内外知名上游药械供应商的经销权，拥有覆盖山东省内全部 等级医院的销售网络，打造了包含药品、器械、中药饮片和体外诊断试剂等多品 类的配送体系，依托自有现代医药物流配送中心，为客户提供更专业、高效的一 站式供应链服务。自 2020 年公司开始战略聚焦，三年时间完成战略转型，公司 营业总收入自 2023 年一季度开始进入稳定常态，收入规模单个季度超 20 亿元， 并且 2023 年四季度、2024 年一季度和二季度均恢复盈利（2024 年季度盈利超过 150 ...

瑞康医药集团股份有限公司 1 | | | 往来方与 上市公司 | 上市公司核 | 年期初 2024 | 2024 年半年 度往来累计 | 2024 年半 年度往来 | 2024 年半 年度偿还 | 年半年 2024 | 往来 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金往来方名称 | | | 算的会计科 | 往来资金余 | | | | 度末往来资 | 形成 | 往来性质 | | | | 的关联关 | 目 | 额 | 发生金额 | 资金的利 | 累计发生 | 金余额 | 原因 | | | | | 系 | | | (不含利息) | 息(如有) | 金额 | | | | | 瑞康时代医药(湖北)有限公司 | | 子公司 | 其他应收款 | 2,951.10 | | | | 2,951.10 | 借款 | 非经营性往来 | | 湖南瑞康医药有限公司 | | 子公司 | 其他应收款 | 11.67 | | | | 11.67 | 借款 | 非经营性往来 | | 黑龙江瑞康世纪医药有限公司 | | 子公司 | 其他 ...

Financial Performance - Revenue for the reporting period was RMB 4,031,665,203.80, a decrease of 1.18% compared to the same period last year[26] - Net profit attributable to shareholders of the listed company was RMB 31,025,324.74, an increase of 1.17% year-on-year[26] - Net cash flow from operating activities was RMB 9,333,575.16, a significant decrease of 94.78% compared to the same period last year[26] - Total assets at the end of the reporting period were RMB 15,725,268,636.69, a decrease of 5.89% compared to the end of the previous year[26] - The company's net profit after deducting non-recurring gains and losses was RMB 6,207,108.97, a significant increase of 105.48% year-on-year[26] - The weighted average return on equity (ROE) was 0.57%, a slight increase of 0.01 percentage points compared to the same period last year[26] - Non-recurring gains and losses amounted to RMB 24,818,215.77, primarily from the disposal of non-current assets and government subsidies[31] - The company's basic earnings per share (EPS) was RMB 0.0206, an increase of 0.98% compared to the same period last year[26] - Revenue for the reporting period was 4,031,665,203.80 yuan, a decrease of 1.18% compared to the same period last year[58] - Sales expenses decreased by 26.57% to 190,452,112.10 yuan, reflecting cost optimization efforts[58] - Net cash flow from operating activities dropped significantly by 94.78% to 9,333,575.16 yuan[58] - Pharmaceutical sales accounted for 75.22% of total revenue, showing a 3.64% year-over-year increase[61] - Medical device sales declined by 14.97% to 916,852,346.02 yuan, contributing 22.74% to total revenue[61] - Rental business revenue surged by 96.64% to 17,086,716.01 yuan, indicating strong growth in this segment[60] - Liaocheng region showed the highest revenue growth among regions, increasing by 16.51% to 116,869,761.41 yuan[61] - R&D investment decreased by 12.53% to 5,479,545.12 yuan, reflecting a shift in resource allocation[58] - The company's financial expenses decreased by 38.26% to 83,340,701.82 yuan, indicating improved financial management[58] - Cash and cash equivalents decreased by 4.59% to 4.041 billion, accounting for 25.70% of total assets[64] - Accounts receivable increased by 2.36% to 3.912 billion, representing 24.88% of total assets[64] - Inventory decreased by 0.81% to 926.475 million, accounting for 5.89% of total assets[64] - Short-term borrowings decreased by 4.07% to 5.530 billion, representing 35.17% of total assets[64] - Long-term borrowings increased by 0.52% to 326.852 million, accounting for 2.08% of total assets[64] - The company invested 53.951 million in the reporting period, a 100% increase compared to the same period last year[69] - The company's subsidiary, Maanshan Tongxing Pharmaceutical Co., Ltd., generated a net profit of 36.886 million[75] - Revenue for the first half of 2024 reached 4,031,665,203.80 RMB, a slight decrease from 4,079,932,498.77 RMB in the same period last year[163] - Operating costs for the first half of 2024 were 3,525,841,738.41 RMB, compared to 3,546,769,335.88 RMB in the first half of 2023[163] - Net profit for the first half of 2024 was 40,551,984.90 RMB, slightly higher than 41,586,431.75 RMB in the same period last year[164] - Basic earnings per share for the first half of 2024 were 0.0206 RMB, compared to 0.0204 RMB in the first half of 2023[164] - Parent company revenue for the first half of 2024 was 3,311,165,233.78 RMB, a slight decrease from 3,325,036,971.10 RMB in the same period last year[166] - Parent company operating costs for the first half of 2024 were 2,965,228,111.82 RMB, compared to 2,984,896,234.86 RMB in the first half of 2023[167] - Parent company net profit for the first half of 2024 was 144,964,645.39 RMB, a significant increase from 21,903,332.33 RMB in the same period last year[168] - Basic earnings per share for the parent company in the first half of 2024 were 0.0963 RMB, compared to 0.0146 RMB in the first half of 2023[168] - Sales of goods and services received cash of 4.044 billion yuan in the first half of 2024, a decrease from 4.443 billion yuan in the same period of 2023[169] - Net cash flow from operating activities was 9.33 million yuan in the first half of 2024, significantly lower than 178.68 million yuan in the same period of 2023[169] - Net cash flow from investing activities was 256.65 million yuan in the first half of 2024, compared to 576.13 million yuan in the same period of 2023[170] - Net cash flow from financing activities was 34.78 million yuan in the first half of 2024, an improvement from a negative 346.84 million yuan in the same period of 2023[170] - The company's cash and cash equivalents increased by 300.76 million yuan in the first half of 2024, reaching a total of 772.70 million yuan at the end of the period[170] - Parent company's sales of goods and services received cash of 3.338 billion yuan in the first half of 2024, down from 4.001 billion yuan in the same period of 2023[171] - Parent company's net cash flow from operating activities was negative 249.03 million yuan in the first half of 2024, compared to positive 1.395 billion yuan in the same period of 2023[171] - Parent company's net cash flow from investing activities was 71.32 million yuan in the first half of 2024, up from 18.84 million yuan in the same period of 2023[172] - Parent company's net cash flow from financing activities was 575.05 million yuan in the first half of 2024, a significant improvement from a negative 1.251 billion yuan in the same period of 2023[172] - Parent company's cash and cash equivalents increased by 397.33 million yuan in the first half of 2024, reaching a total of 526.95 million yuan at the end of the period[172] - The company's comprehensive income for the first half of 2024 was RMB 25.3 million[175] - Total owner's equity at the end of the period was RMB 5.69 billion, an increase from the beginning of the period[176] - The company allocated RMB 19.5 million for profit distribution to shareholders[175] - Capital reserves decreased by RMB 133.91 million due to owner's capital reduction[175] - Special reserves remained unchanged at RMB 0.00[176] - Retained earnings increased by RMB 39.09 million from owner's capital contributions[175] - The company's total assets at the end of the period were RMB 5.49 billion[176] - Other comprehensive income increased by RMB 11.46 million[175] - The company's equity balance at the beginning of the period was RMB 5.63 billion[173] - Profit distribution to shareholders amounted to RMB 19.5 million[175] - Total equity attributable to parent company owners at the end of the period was 5.75 billion[177] - Comprehensive income for the period increased by 30.6 million[177] - Total revenue for the first half of 2024 was 67.2 million[178] - Owner's equity and capital reduction amounted to 180 million[178] - Special reserves at the end of the period were 5.79 billion[179] - Capital accumulation fund increased by 3.70 billion[177] - General risk provision increased by 152 million[177] - Profit distribution to owners (or shareholders) was 30.6 million[177] - Other comprehensive income increased by 81.1 million[177] - Total equity at the end of the period was 5.79 billion[179] - Share capital at the end of the period was 1,504,710.4 thousand yuan[181] - Capital reserve increased by 133.9 million yuan during the period[181] - Comprehensive income for the period totaled 144.9 million yuan[181] - Profit distribution to owners amounted to 19.56 million yuan[182] - Total owner's equity at the end of the period was 6,039,095.8 thousand yuan[182] - Other equity tools remained unchanged at 0.00 thousand yuan[181] - Special reserve usage was not reported for the period[182] - Undistributed profits increased by 125.4 million yuan during the period[181] - Total comprehensive income for the period was 144.9 million yuan[181] - Owner's equity internal transfers were not reported for the period[182] - Total comprehensive income for the period amounted to 3,332.33 million[184] - Total owner's equity at the end of the period was 5,852,372.8 million[185] Business Strategy and Expansion - The company continues to focus on the traditional pharmaceutical distribution industry while actively expanding into the traditional Chinese medicine sector[34] - The company has established a comprehensive distribution network covering major hospitals in Shandong Province, offering a multi-category delivery system for both pharmaceuticals and medical devices[35] - The company is actively involved in the development of traditional Chinese medicine (TCM), leveraging national policies to promote TCM innovation and industry transformation[37][38] - The company has implemented a cross-departmental project management model to enhance product competitiveness and accelerate product development[39] - The pharmaceutical and medical device distribution segment focuses on optimizing product structure and expanding into self-developed medical devices and TCM products[40] - The company has improved supply chain efficiency and market responsiveness through SPD (Supply Chain Management), smart TCM pharmacies, and centralized distribution projects[42] - The in-vitro diagnostics segment has completed strategic adjustments in 2023, focusing on key markets in Shandong and providing comprehensive laboratory solutions[43] - The digital healthcare segment integrates multiple medical services, offering a full-cycle health management ecosystem for users[44] - The company's health management segment provides comprehensive services for chronic diseases such as diabetes and hypertension, utilizing advanced wearable devices for data collection and analysis[45] - The logistics segment achieved significant cost reductions through optimized staffing and variable expense control, and improved delivery efficiency with a next-day delivery model from Yantai to Jinan[47] - The logistics segment successfully launched a billing platform, enhancing logistics performance management efficiency[47] - The logistics segment expanded its vaccine and cold chain storage and transportation business in Shandong Province, achieving cost savings and efficiency improvements[47] - The traditional Chinese medicine (TCM) segment developed intelligent equipment for TCM liquefaction, achieving fully automated and intelligent production processes[49] - The TCM segment collaborated with Guangdong Pharmaceutical University to develop a lipid-lowering TCM new drug, "Zhenzhu Tiaozhi Capsule," which has received clinical trial approval[49] - The company's direct sales network covers all secondary and above hospitals in Shandong Province, providing strong business synergy and competitive advantage[52] - The company has extended its industrial chain upstream to include medical device production and new drug R&D, and downstream to include TCM clinics and pharmacies[53] - The company's logistics segment has national third-party logistics qualifications, enabling nationwide pharmaceutical distribution and cold chain services[54] - The company's digital transformation has resulted in over 50 core business systems running on Amazon Web Services for 36 months, achieving cost reduction and flexible deployment capabilities[55] - The company completed the construction of its core SAP business system API service platform, enhancing digital transformation[56] - The company is exploring new business areas such as high-end medical devices and traditional Chinese medicine, but faces risks of underperformance in these investments[79] Corporate Governance and Shareholder Relations - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[6] - The company held a temporary shareholders' meeting on January 8, 2024, with an investor participation rate of 12.73%[86] - The annual shareholders' meeting on May 21, 2024, had an investor participation rate of 14.26%[86] - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the first half of the year[88] - The company has no equity incentive plan in place during the reporting period[89] - The employee stock ownership plan involved 97 employees holding a total of 7,598,300 shares, accounting for 0.50% of the company's total share capital[90] - The company reversed a previously accrued expense of 19,298,822.82 yuan due to the termination of the employee stock ownership plan[92] - The company decided to terminate the 2022 employee stock ownership plan early on April 29, 2024, due to changes in market conditions and employee circumstances[92] - The company emphasizes the importance of protecting shareholders' rights and promoting healthy development through strict adherence to corporate governance laws and regulations[97] - The company actively engages with investors through various channels, including phone, online, and on-site visits, to maintain transparent communication[98] - The company focuses on maximizing investor value by analyzing market conditions and adjusting strategies to ensure shareholders benefit from the company's growth[99] - The company's directors and senior management strictly adhered to their commitment to limit the transfer of shares to no more than 25% of their total holdings during their tenure[111] - No non-operational fund occupation by controlling shareholders or other related parties was reported during the period[112] - The company reported no instances of违规对外担保 (illegal external guarantees) during the reporting period[113] - The semi-annual financial report was not audited[114] - The company did not undergo any破产重整 (bankruptcy restructuring) during the reporting period[115] - Limited-sale shares decreased by 1,500,000 shares, from 140,618,923 shares (9.35%) to 139,118,923 shares (9.25%)[138] - Unlimited-sale shares increased by 1,500,000 shares, from 1,364,091,548 shares (90.65%) to 1,365,591,548 shares (90.75%)[138] - Total number of shares remained unchanged at 1,504,710,471 shares (100.00%)[139] - The total number of ordinary shareholders at the end of the reporting period was 79,704[140] - Zhang Renhua, an individual shareholder, holds 13.39% of the shares, totaling 201,498,159 shares, with 90,874,100 shares pledged[140] - Han Xu, another individual shareholder, holds 12.33% of the shares, totaling 185,491,897 shares, with 101,100,000 shares pledged[140] - Jingzhou Merchants Huize Pharmaceutical Investment Partnership holds 5.00% of the shares, totaling 75,235,525 shares[140] - Great Wall Guorong Investment Management, a state-owned legal entity, holds 1.78% of the shares, totaling 26,845,667 shares[140] - The company's top 10 shareholders did not engage in any repurchase transactions during the reporting period[142] - The company's actual controller did not change during the reporting period[144] Risk Management and Legal Issues - The company faces risks from policy changes, including potential impacts on profitability due to healthcare reform and pricing mechanism adjustments[77] - The company is actively managing accounts receivable risks through credit management and innovative financial solutions[78] - A significant诉讼 (litigation) involving 36.21 million RMB with单县中心医院 (Shanxian Central Hospital) is currently in二审 (second instance)[116] - Another诉讼 (litigation) with陕西柏达建宏生物技术有限公司 (Shaanxi Baida Jianhong Biotechnology Co., Ltd.) for 13.6 million RMB has been resolved through诉中调解 (mediation during litigation), with the company having paid 6.764 million RMB[116] - The company has ongoing litigation cases with amounts involved, such as a case with Shouguang People's Hospital involving 84 million RMB[117] - A case with Fuzhou Keyang Medical Equipment Co., Ltd. involving 10.13 million RMB is under trial[117] - A case with Heze Jinyue Ruikang Pharmaceutical Co., Ltd. involving 12.7463 million RMB was dismissed[117] - A case with Tianjin Guohui Health Technology Co., Ltd. involving 47.4588 million RMB was settled out of court[117] - A case with Zhou Jun and Ruikang Pharmaceutical Changzhou Co., Ltd. involving 48.86 million RMB has been adjudicated[117] - A case with Sun Minfang and Yang Luya involving 38.4704 million RMB is under execution[117] - A case with Lanzhou Mingda Business Consulting Co., Ltd. involving 14.7415 million RMB was withdrawn[117] - The company has 2 ongoing execution cases involving 611,200 RMB and 5 completed execution cases involving 2.8137 million RMB[118] - The company has 4 ongoing litigation cases as the plaintiff involving 5.325 million RMB and 5 cases as the defendant involving 28.1586 million RMB[118] Human Resources and Corporate Culture - Established "Ruikang Academy" to enhance employee training and develop a loyal workforce[101] - Implemented integrated supply chain management to optimize project lifecycle control[104] - Focused on building win-win cooperation models with partners and maintaining fair competition[105] - Promoted energy conservation and environmental protection measures across all departments[106] - Encouraged resource recycling and reuse, such as collecting insulation boxes and packaging materials[107] - Actively participated in social welfare and charity activities, contributing to local economic development[108] -

证券代码：002589 证券简称：瑞康医药 公告编号：2024-026 瑞康医药集团股份有限公司 关于股东权益变动的提示性公告 股东张仁华保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 1、瑞康医药集团股份有限公司(以下简称"公司")实际控制人张仁华女士于 2024 年 8 月 1 日与北京岩泉财富投资管理有限公司-岩泉 8 号私募证券投资基金 （以下简称"岩泉 8 号基金"）签署了《股份转让协议》，拟通过协议转让方式 向岩泉 8 号基金转让公司 76,000,000 股无限售流通股，占公司总股本的 5.05%。 2、本次转让完成后，岩泉 8 号基金将成为公司持股 5%以上股东。本次协议 转让之受让方岩泉 8 号基金承诺：在协议转让股份过户登记完成后的 6 个月内不 减持本次协议转让所受让的公司股份。 3、本次权益变动不会导致公司实际控制权的变化，也不涉及要约收购等事 项，不存在损害公司及其他股东利益的情形。 4、本次权益变动后，张仁华女士及其一致行动人韩旭先生仍为公司的实际 控制人，合计持 ...

瑞康医药集团股份有限公司 简式权益变动报告书（一） 上市公司名称：瑞康医药集团股份有限公司 股票上市地点：深圳证券交易所 股票简称：瑞康医药 股票代码：002589.SZ 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证 券法》、《上市公司收购管理办法》、《公开发行证券公司信息披露内容与格式 准则第 15 号——权益变动报告书》及相关的法律、法规和规范性文件编制本报 告书。 二、截至本报告签署日，信息披露义务人签署本报告书已获得必要的授权和 批准，其履行亦不违反信息披露义务人章程或内部规则中的任何条款，或与之相 冲突。 三、依据《中华人民共和国证券法》等法律法规及规范性文件的规定，本报 告书已全面披露了信息披露义务人在瑞康医药集团股份有限公司中拥有权益的 股份变动情况。 信息披露义务人：张仁华 住所：山东省烟台市芝罘区二马路***号 通讯地址：山东省烟台市芝罘区凤鸣路 103 号 13 号楼 一致行动人：韩旭 通讯地址：山东省烟台市芝罘区凤鸣路 103 号 13 号楼 股份变动性质：股份减少（协议转让） 签署日期：2024 年 8 月 1 日 信息披露义务人声明 截至本报告书签署日，除本报告 ...

瑞康医药集团股份有限公司 简式权益变动报告书（二） 上市公司名称：瑞康医药集团股份有限公司 股票上市地点：深圳证券交易所 股票简称：瑞康医药 股票代码：002589.SZ 信息披露义务人名称：北京岩泉财富投资管理有限公司——岩泉 8 号私募证 券投资基金 住所：北京市平谷区林荫北街 13 号信息大厦 802 室 通讯地址：北京市平谷区林荫北街 13 号信息大厦 802 室 股份变动性质：股份增加（协议转让） 签署日期：2024 年 8 月 1 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证 券法》、《上市公司收购管理办法》、《公开发行证券公司信息披露内容与格式 准则第 15 号——权益变动报告书》及相关的法律、法规和规范性文件编制本报 告书。 二、截至本报告签署日，信息披露义务人签署本报告书已获得必要的授权和 批准，其履行亦不违反信息披露义务人章程或内部规则中的任何条款，或与之相 冲突。 三、依据《中华人民共和国证券法》等法律法规及规范性文件的规定，本报 告书已全面披露了信息披露义务人在瑞康医药集团股份有限公司中拥有权益的 股份变动情况。 截至本报告书签署日，除本报 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2024-025 瑞康医药集团股份有限公司 关于公司董事、监事及高管团队增持计划实施完成的公告 一、计划增持主体的基本情况 1、烟台慧投，公司董事、监事及高管团队李喆、杨博、张寿凯、张岩成立 的合伙企业。 2、本次增持计划公告前 12 个月内未披露增持计划。 3、本次公告前 6 个月内不存在减持情况。 二、增持计划的主要内容 1、增持原因：基于对公司未来发展前景的信心以及对公司长期价值的认同， 为了更好地支持公司持续、稳定、健康的发展拟实施增持计划。 信息披露义务人烟台慧投投资发展合伙企业（有限合伙）保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员 保证公告内容与信息披露义务人提供的信息一致。 特别提示： 瑞康医药集团股份有限公司（以下简称"公司"）于 2023 年 12 月 23 日披露 了《关于公司董事、监事及高管团队增持计划的公告》，公司董事、监事及高管 团队自上述公告披露之日起 6 个月内拟通过深圳证券交易所集中竞价方式，增 持公司股份 600-1,000 万元。 增持计划的进展情况：截至 2 ...